a significant trendP=0.003
A significant trend towards a prolonged time to CNS relapse following intravenous rituximab treatment was observed (P=0.003; Fig. 4 ), but neither intravenous HD-MTX nor intrathecal injection reduced the incidence of CNS recurrence (P=0.689 and P=0.876, respectively).